Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) greater than or equal to (\>=) 35 to less than or equal to (\<=) 50 kilogram per meter square (kg/m\^2) at screening~* Stable weight (that is, change of \<= 5 percent \[%\] within 12 weeks before screening based on medical or participant reported history)~* Hemoglobin A1c of \>= 6.5% and \<= 9.5% at screening and meets one of the inclusion criteria as: (a) on diet and exercise alone \>= 12 weeks prior to screening; (b) on stable dose of single oral antihyperglycemic agent (AHA) or dual-combination oral AHAs for \>= 12 weeks prior to screening~* Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of birth control, or (d) Not heterosexually active~* Willing and able to adhere to specific the prohibitions and restrictions~Exclusion Criteria:~* History of obesity with a known secondary cause (example, Cushing's disease/syndrome)~* History of Type 1 diabetes mellitus, diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Fasting C-peptide less than (\<) 0.7 nanogram per milliliter (ng/mL) at screening~* Fasting fingerstick glucose of \>= 270 milligram per deciliter (mg/dL) (\>=15 millimoles per liter \[mmol/L\]) on Day 1~* Ongoing, inadequately controlled thyroid disorder as assessed by the investigator's review of the participant's medical history. Participants taking thyroid hormone replacement therapy must be on stable doses for at least 6 weeks before the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-64565111 Dose Level 1 (Type: EXPERIMENTAL): Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
- JNJ-64565111 Dose Level 2 (Type: EXPERIMENTAL): Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
- JNJ-64565111 Dose Level 3 (Type: EXPERIMENTAL): Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).